Search results for "NEUROBLASTOMA"

showing 10 items of 239 documents

Exon-level expression analyses identify MYCN and NTRK1 as major determinants of alternative exon usage and robustly predict primary neuroblastoma out…

2012

BACKGROUND: Using mRNA expression-derived signatures as predictors of individual patient outcome has been a goal ever since the introduction of microarrays. Here, we addressed whether analyses of tumour mRNA at the exon level can improve on the predictive power and classification accuracy of gene-based expression profiles using neuroblastoma as a model. METHODS: In a patient cohort comprising 113 primary neuroblastoma specimens expression profiling using exon-level analyses was performed to define predictive signatures using various machine-learning techniques. Alternative transcript use was calculated from relative exon expression. Validation of alternative transcripts was achieved using q…

Cancer ResearchMedizinComputational biologyBiologyexon arraysBioinformaticsN-Myc Proto-Oncogene ProteinExonNeuroblastomaRisk FactorsNeuroblastomaCell Line TumorGene expressionmedicineHumansRNA MessengerReceptor trkAGeneSurvival analysisOncogene ProteinsN-Myc Proto-Oncogene ProteinGene Expression ProfilingInfantNuclear ProteinsGenetics and GenomicspredictionExonsalternative transcript usemedicine.diseasePrognosisSurvival AnalysisGene expression profilingOncologyChild PreschoolPAMDNA microarray
researchProduct

Abstract 2435: Amplification of CDK4 and MDM2 is associated with atypical clinical features in high risk neuroblastoma patients

2016

Abstract MYCN-amplification and 11q-deletion are important, although incomplete, markers of high-risk neuroblastoma. Thus, characterization of additional genomic alterations that can be used as prognostic and/or predictive markers is of clinical importance in order to provide best treatment possible. By using SNP-microarrays we identified a small group of neuroblastomas with high grade amplification of one or multiple loci on 12q, commonly involving the potential oncogenic target genes CKD4 (12q13-14) and/or MDM2 (12q15). The CDK4 and MDM2 regions were co-amplified in 13/16 samples, two tumors had CDK4-amplification in absence of MDM2-amplification while one tumor had MDM2-amplification wit…

Cancer ResearchMutationDNA repairmedicine.medical_treatmentCancerBiologymedicine.diseasemedicine.disease_causeTargeted therapyOncologyNeuroblastomaCancer researchmedicinebiology.proteinMdm2neoplasmsExome sequencingChromosome 12Cancer Research
researchProduct

Angiogenesis in neuroblastoma: relationship to survival and other prognostic factors in a cohort of neuroblastoma patients.

2000

PURPOSE: To study angiogenesis in neuroblastoma, using morphometric and computerized image analysis, and correlate the results with survival and other prognostic factors. PATIENTS AND METHODS: Sixty-nine patients from the Spanish Cooperative Study for Neuroblastoma were studied. Tumoral angiogenesis was studied using an avidin-biotin immunoperoxidase technique with an anti-CD34 antibody. Vascular parameters (VPs) were analyzed by a computerized system. Statistical analysis was also performed. RESULTS: Sixty-six samples had adequate tumoral tissue, and their tumoral vessels were counted. Endothelial cells were more prominent in pure neuroblastomas than in maturing and more mature tumors. VP…

Cancer ResearchPathologymedicine.medical_specialtyImmunoperoxidaseAngiogenesisbusiness.industrymedicine.diseaseNeovascularizationOncologyNeuroblastomamedicineImmunohistochemistryHistopathologyStage (cooking)medicine.symptombusinessSurvival rate
researchProduct

Neural and mesenchymal differentiations in Ewing's sarcoma cell lines. Morphological, immunophenotypic, molecular biological and cytogenetic evidence

1995

Three established Ewing's sarcoma (ES) cell lines (TC106, 6647, A4573), grown both in vitro and as xenograft tumors, were analyzed. In all 3 lines and tumors, the ES characteristic reciprocal translocation (11;22), as well as the presence of the ES-associated p30/32M1C2 antigen, were documented. However, these cell lines showed discrepancies in their neural and mesenchymal differentiation. The TC106 line was characterized by expression of the neuroendocrine marker secretogranin II (SgII) which was detectable by Northern blot and by radioimmunological detection (RIA) in the culture medium of secretoneurin, a proteolytic product of SgII. In contrast, TC106 cells were immunohistochemically and…

Cancer ResearchPathologymedicine.medical_specialtyRadioimmunoassayMice NudeSarcoma EwingBiologyNeuroendocrine differentiationImmunophenotypingMiceNeuroblastomaTumor Cells CulturedmedicineAnimalsHumansNeuroectodermal Tumors Primitive PeripheralNorthern blotMice Inbred BALB CSecretoneurinNeuropeptidesMesenchymal stem cellEwing's sarcomaChromogranin ABlotting Northernmedicine.diseaseImmunohistochemistryChromosome BandingOncologySecretogranin IICell cultureKaryotypingbiology.proteinCancer researchSarcomaInternational Journal of Cancer
researchProduct

Abstract A02: Neuroblastoma patient-derived orthotopic xenografts: Clinically relevant models for drug testing

2016

Abstract Widespread metastasis is a major problem for the treatment of high-risk neuroblastoma. Relevant neuroblastoma animal models are hence needed to study and target high-risk metastatic neuroblastoma. We developed neuroblastoma patient-derived orthotopic xenografts (PDXs) using viably cryopreserved or fresh patient neuroblastoma fragments which were implanted orthotopically into immunodeficient NSG mice. Immunohistochemistry showed that PDXs retain neuroblastoma markers and a highly infiltrative growth pattern. Importantly, we found distant metastasis to lungs, liver and bone marrow. Single nucleotide polymorphism array analysis confirmed that PDXs maintain patient-specific chromosomal…

Cancer ResearchPathologymedicine.medical_specialtyTumor microenvironmentOncogenebusiness.industryCancermedicine.diseasePediatric cancerMetastasisLymphatic systemmedicine.anatomical_structureOncologyNeuroblastomamedicineBone marrowbusinessCancer Research
researchProduct

Abstract B23: Neuroblastoma patient-derived orthotopic xenografts: Clinically relevant models for drug testing

2016

Abstract Background: We previously established neuroblastoma patient-derived orthotopic xenografts (PDXs) by implanting patient neuroblastoma fragments into immunodeficient NSG mice. SNP array analysis confirmed that PDXs maintain patient-specific chromosomal aberrations 1p del, MYCN amp and 17q gain. Immunohistochemistry showed that PDXs retain neuroblastoma markers and a highly infiltrative growth pattern. Importantly, we found spontaneous distant metastasis to lungs, liver and bone marrow. In vitro cultures established from the PDXs express neuroblastoma markers and retain their tumorigenic and metastatic ability in vivo after orthotopic injection. Methods and Results: Given the importan…

Cancer ResearchPathologymedicine.medical_specialtyTumor microenvironmentOncogenebusiness.industrymedicine.diseaseLymphatic systemmedicine.anatomical_structureOncologyStromaIn vivoTumor progressionNeuroblastomamedicineBone marrowbusinessClinical Cancer Research
researchProduct

Abstract 495: Amplification of chromosomal regions 12q13-14 and 12q15 defines a distinct subgroup of high-risk neuroblastoma patients and is associat…

2015

Abstract Neuroblastoma is a pediatric cancer of the sympathetic nervous system with wide heterogeneity regarding clinobiological subtypes, ranging from patients with tumors of spontaneous regression to patients with aggressive tumors with fatal outcome despite multimodal treatment. MYCN-amplification and 11q-deletion are important, although incomplete, markers of high-risk neuroblastoma. Thus, characterization of additional genomic alterations that can be used as prognostic and/or predictive markers is of clinical importance in order to provide best possible treatment. From genomic profiles generated through high-density SNP microarrays we identified a group of neuroblastomas (14 primary tu…

Cancer ResearchPathologymedicine.medical_specialtymedicine.medical_treatmentCancerBiologyAmpliconmedicine.diseasePediatric cancerTargeted therapyOncologyNeuroblastomaChromosomal regionCancer researchmedicineneoplasmsChromosome 12Exome sequencingCancer Research
researchProduct

Children may not benefit from neuroblastoma screening at 1 year of age. Updated results of the population based controlled trial in Germany

2003

Neuroblastoma is the second most frequent malignancy in childhood. We investigated whether screening for neuroblastoma at 1 year of age reduces the incidence of metastatic disease or mortality. Screening was offered in 6 of the 16 German states from 1995 to 2000 with the remaining states serving as controls. We studied 2,581,188 children in the screening area born between 1994 and 1999 and 2,117,600 in the control area. We compared mortality from neuroblastoma and the incidence of disseminated disease in the two groups. The screened group and the control group had similar rates of stage 4 neuroblastoma and mortality due to neuroblastoma. Comparison of the screened group and the control area…

Cancer ResearchPediatricsmedicine.medical_specialtyPopulationCohort StudiesNeuroblastomaPredictive Value of TestsGermanyNeuroblastomaEpidemiologyHumansMass ScreeningMedicineOverdiagnosiseducationFalse Negative ReactionsMass screeningNeoplasm Stagingeducation.field_of_studybusiness.industryIncidenceIncidence (epidemiology)Infantmedicine.diseaseOncologyScreening for NeuroblastomaChild PreschoolPopulation SurveillancebusinessProgram EvaluationCohort studyCancer Letters
researchProduct

Estrogen receptor α regulates non-canonical autophagy that provides stress resistance to neuroblastoma and breast cancer cells and involves BAG3 func…

2015

AbstractBreast cancer is a heterogeneous disease and approximately 70% of newly diagnosed breast cancers are estrogen receptor (ER) positive. Out of the two ER types, α and β, ERα is the only ER that is detectable by immunohistochemistry in breast cancer biopsies and is the predominant subtype expressed in breast tumor tissue. ER-positive tumors are currently treated with anti-hormone therapy to inhibit ER signaling. It is well known that breast cancer cells can develop endocrine resistance and resistance to anti-hormone therapy and this can be facilitated via the autophagy pathway, but so far the description of a detailed autophagy expression profile of ER-positive cancer cells is missing.…

Cancer ResearchProgrammed cell deathImmunologyEstrogen receptorBreast NeoplasmsBiologyBAG3Cellular and Molecular NeuroscienceNeuroblastomaBreast cancermedicineAutophagyEstrogen Receptor betaHumansPrecision MedicineEstrogen receptor betaPI3K/AKT/mTOR pathwayAdaptor Proteins Signal TransducingEstrogen Replacement TherapyEstrogen Receptor alphaCell Biologymedicine.disease3. Good healthCell biologyGene Expression Regulation NeoplasticCancer cellMCF-7 CellsOriginal ArticleFemaleApoptosis Regulatory ProteinsEstrogen receptor alphaSignal TransductionCell Death & Disease
researchProduct

Neuroblastoma with MYCN amplification plus 11q deletion: immunohistochemical expression of angiogenic factors

2010

Neuroblastoma (NB) is an extra-cranial solid neoplasm in childhood. Genetic markers as MYCN amplification (MNA) and deletion of 11q (11q ) are considered factors with an adverse prognosis. Usually, an inverse relationship between MNA and 11q is found. Approximately 13% of the MNA cases present with 11q . These cases show a dramatic decline in survival rates. Hypoxia-inducible factor-2a (HIF-2a) protein expression has been described as an indicator of poor outcome, has been correlated with an aggressive phenotype in NB, and serves as a marker for stem cell-like phenotypes. Additionally, HIF-2a positive cells strongly express vascular endothelial growth factor (VEGF) and, as such, could be in…

Cancer Researchmedicine.diagnostic_testCancerBiologymedicine.diseaseVascular endothelial growth factorchemistry.chemical_compoundchemistryGenetic markerNeuroblastomaGene duplicationGeneticsCancer researchmedicineImmunohistochemistryMultiplex ligation-dependent probe amplificationMolecular BiologyFluorescence in situ hybridizationCancer Genetics and Cytogenetics
researchProduct